Istvan Teplan
Semmelweis University
82 Papers
584 Citations
Istvan Teplan is an academic researcher from Semmelweis University. The author has contributed to research in topics: Gonadotropin-releasing hormone & In vivo. The author has an hindex of 17, co-authored 82 publications. Previous affiliations of Istvan Teplan include Creighton University.
Chat about Author
Papers
Metal ion-induced conformational changes of phosphorylated fragments of human neurofilament (NF-M) protein.
Miklós Hollósi,L. Ürge,András Perczel,Judit Kajtár,Istvan Teplan,Laszlo Otvos,Gerald D. Fasman +6 more
TL;DR: A mechanism of metal binding to the phosphofragments is proposed which may be relevant to the formation of neurofibrillary tangles in Alzheimer's disease.
77
Desensitization of luteinizing hormone release in cultured pituitary cells by gonadotropin-releasing hormone.
TL;DR: The time curve of desensitization supports the idea that GnRH action has two-phases: an acute effect which cannot be desensitized, and a secondary phase which can be densensitized.
52
Gonadotropin-releasing hormone analogue conjugates with strong selective antitumor activity.
Istvan Palyi,B. Vincze,Sándor Lovas,I. Mezö,János Pató,Adrienn Kalnay,Gizella Turi,D. Gaál,R. Mihalik,I. Péter,Istvan Teplan,Richard F. Murphy +11 more
TL;DR: The additional specificity of P-X-peptides compared with free peptides for direct antiproliferative effects on the cancer cells but not for interactions in the pituitary indicates the therapeutic potential of the conjugates.
43
Synthesis of gonadotropin-releasing hormone III analogs. Structure-antitumor activity relationships.
Imre Mezo,Sándor Lovas,Istvan Palyi,B. Vincze,Adrien Kálnay,Gizella Turi,Zsolt Vadasz,Janos Seprodi,Miklós Idei,Geza Toth,Éva Gulyás,Ferenc Ötvös,Mariann Mák,Judit Horvath,Istvan Teplan,Richard F. Murphy +15 more
TL;DR: In this paper, analogs of the gonadotropin-releasing hormone III (GnRH-III) were synthesized to investigate the structural basis for the improved antitumor activity.
40
Luteinizing hormone-releasing hormone analogs with increased anti-ovulatory activity.
Judit Erchegyi,Judit Erchegyi,David H. Coy,David H. Coy,Mary V. Nekola,Mary V. Nekola,Esther J. Coy,Esther J. Coy,Andrew V. Schally,Andrew V. Schally,I. Mezö,Istvan Teplan +11 more
TL;DR: A series of LH-RH antagonist analogs has been developed in which inhibitory activities have been increased to a potentially clinically useful level and induce full blockade of ovulation at single doses as low as 10 μg per rat (50 μg/kg).
35